The IPO4 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the IPO4 gene. This heterogeneous pool of Jurkat cells provides a loss-of-function model for studying Importin-4-mediated nuclear transport without clonal isolation, enabling functional interrogation of nucleocytoplasmic trafficking in a T-cell context.
Jurkat cells, derived from a human acute T cell leukemia, are a standard model for T lymphocyte activation, signaling, and apoptosis. They recapitulate key aspects of T-cell biology, including TCR-mediated signaling and Fas-dependent cell death, and their well-characterized signaling networks facilitate gene-editing studies focused on leukemic T-cell physiology.
IPO4 (Importin-4) operates as a nuclear transport receptor that imports cargo proteins containing nuclear localization signals. In conjunction with Importin ?? and the small GTPase Ran, IPO4 shuttles ribosomal proteins and transcription factors such as c-Myc through the nuclear pore complex. The import cycle is governed by the Ran GTP/GDP gradient, ensuring directional transport. By mediating nuclear delivery of these substrates, IPO4 links cytoplasmic events to ribosome biogenesis and transcriptional control. Knockout of IPO4 is predicted to block nuclear accumulation of its cargoes, disrupting downstream processes.
In Jurkat T cells, loss of IPO4 function impairs nuclear import of ribosomal proteins and transcription factors, potentially compromising ribosome assembly and altering gene expression profiles. Given the high biosynthetic demands of leukemic cells, defective ribosome production may reduce translational capacity and cell proliferation. Concurrently, diminished nuclear c-Myc levels can interfere with cell cycle progression and survival. This polyclonal knockout model thus offers a system to examine how nuclear transport defects impact T-cell activation, growth, and apoptosis in a leukemia-relevant setting.
This product supports diverse research applications, including dissection of importin pathways, functional analysis of IPO4 in T-cell biology, and drug target validation. Typical assays include immunofluorescence localization of cargo proteins (e.g., ribosomal protein L5, c-Myc), western blotting for IPO4 confirmation, transcriptomic profiling by RNA-seq, and proliferation/apoptosis measurements. Researchers can employ this model to investigate nuclear transport mechanisms and their relevance to cancer biology. For inquiries, contact Ascent Research.
